Drug intelligence / Profile preview

MEOPA + paracetamol

Development stage: Preclinical
Modality: Small Molecules
Administration: Inhalation, Intravenous, Oral

Overview

MEOPA + paracetamol is a combination therapy consisting of MEOPA (a nitrous oxide and oxygen mixture) and paracetamol (acetaminophen). This combination is used for pain management, particularly in acute settings. MEOPA provides rapid-onset analgesia through its nitrous oxide component, while paracetamol offers longer-lasting pain relief. The combination has been studied for use in pre-hospital settings due to its ease of administration.

Targets

PGHS-1 (Prostaglandin G/H Synthase 1)

Beyond the preview

Go deeper on MEOPA + paracetamol.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MEOPA + paracetamol.

Explore the full profile